Cargando…

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer

Activation of mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) growth signalling is coupled to increased cell proliferation in prostate cancer (PCa). Dysregulation of the DNA replication licensing pathway, a critical step in growth control do...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudderidge, T J, McCracken, S R, Loddo, M, Fanshawe, T R, Kelly, J D, Neal, D E, Leung, H Y, Williams, G H, Stoeber, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360172/
https://www.ncbi.nlm.nih.gov/pubmed/17406359
http://dx.doi.org/10.1038/sj.bjc.6603718
_version_ 1782152982186426368
author Dudderidge, T J
McCracken, S R
Loddo, M
Fanshawe, T R
Kelly, J D
Neal, D E
Leung, H Y
Williams, G H
Stoeber, K
author_facet Dudderidge, T J
McCracken, S R
Loddo, M
Fanshawe, T R
Kelly, J D
Neal, D E
Leung, H Y
Williams, G H
Stoeber, K
author_sort Dudderidge, T J
collection PubMed
description Activation of mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) growth signalling is coupled to increased cell proliferation in prostate cancer (PCa). Dysregulation of the DNA replication licensing pathway, a critical step in growth control downstream of transduction signalling pathways, is associated with development of PCa. In this study we have investigated linkages between the MEK5/ERK5 pathway and DNA replication licensing during prostate carcinogenesis. The effects of increased MEK5/ERK5 signalling on the expression of replication licensing factors Mcm2 and geminin and the proliferation marker Ki67 were studied in an ecdysone-inducible system expressing a constitutively activated mutant of MEK5 in EcR293 cells and in stable ERK5 over-expressing PC3 clones. In parallel, expression of these biomarkers in PCa biopsy specimens (n=58) was studied and compared to clinicopathological parameters. In both in vitro systems induction of MEK5 expression resulted in increased levels of phosphorylated ERK5 and Mcm2, geminin and Ki67 proteins. In PCa specimens average Mcm2 expression was greater than Ki67 and geminin expression (median labelling index (LI) 36.7, 18.1, and 3.4% respectively), consistent with their differential expression according to growth status (P<0.0001). Mcm2, geminin and Ki67 expression were significantly associated with Gleason grade (P=0.0002, P=0.0003, P=0.004); however there was no link with T or M stage. There was a significant relationship between increasing ERK5 expression and increasing Mcm2 (P=0.003) and Ki67 (P=0.009) expression, with non-significant trends seen with increasing MEK5 expression. There were significant associations between Gleason grade and the number of cells traversing G1 phase (Ki67(LI)-geminin(LI); (P=0.001)), with high ERK5 levels associated with both an increase in replication licensed but non-cycling cells (Mcm2(LI)-Ki67(LI); (P=0.01)) and accelerated cell cycle progression (geminin(LI)/Ki67(LI); (P= 0.005)), all indicative of a shift towards increasing proliferative potential. While Mcm2 and Ki67 were both prognostic factors on univariate analysis, only Mcm2 remained an independent prognostic marker on multivariate analysis. Taken together, our data show that induction of MEK5/ERK5 signalling is linked to activation of the DNA replication licensing pathway in PCa, and that the strong prognostic value of MCM proteins may result from their function as relay stations coupling growth regulatory pathways to genome duplication.
format Text
id pubmed-2360172
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23601722009-09-10 Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer Dudderidge, T J McCracken, S R Loddo, M Fanshawe, T R Kelly, J D Neal, D E Leung, H Y Williams, G H Stoeber, K Br J Cancer Molecular Diagnostics Activation of mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) growth signalling is coupled to increased cell proliferation in prostate cancer (PCa). Dysregulation of the DNA replication licensing pathway, a critical step in growth control downstream of transduction signalling pathways, is associated with development of PCa. In this study we have investigated linkages between the MEK5/ERK5 pathway and DNA replication licensing during prostate carcinogenesis. The effects of increased MEK5/ERK5 signalling on the expression of replication licensing factors Mcm2 and geminin and the proliferation marker Ki67 were studied in an ecdysone-inducible system expressing a constitutively activated mutant of MEK5 in EcR293 cells and in stable ERK5 over-expressing PC3 clones. In parallel, expression of these biomarkers in PCa biopsy specimens (n=58) was studied and compared to clinicopathological parameters. In both in vitro systems induction of MEK5 expression resulted in increased levels of phosphorylated ERK5 and Mcm2, geminin and Ki67 proteins. In PCa specimens average Mcm2 expression was greater than Ki67 and geminin expression (median labelling index (LI) 36.7, 18.1, and 3.4% respectively), consistent with their differential expression according to growth status (P<0.0001). Mcm2, geminin and Ki67 expression were significantly associated with Gleason grade (P=0.0002, P=0.0003, P=0.004); however there was no link with T or M stage. There was a significant relationship between increasing ERK5 expression and increasing Mcm2 (P=0.003) and Ki67 (P=0.009) expression, with non-significant trends seen with increasing MEK5 expression. There were significant associations between Gleason grade and the number of cells traversing G1 phase (Ki67(LI)-geminin(LI); (P=0.001)), with high ERK5 levels associated with both an increase in replication licensed but non-cycling cells (Mcm2(LI)-Ki67(LI); (P=0.01)) and accelerated cell cycle progression (geminin(LI)/Ki67(LI); (P= 0.005)), all indicative of a shift towards increasing proliferative potential. While Mcm2 and Ki67 were both prognostic factors on univariate analysis, only Mcm2 remained an independent prognostic marker on multivariate analysis. Taken together, our data show that induction of MEK5/ERK5 signalling is linked to activation of the DNA replication licensing pathway in PCa, and that the strong prognostic value of MCM proteins may result from their function as relay stations coupling growth regulatory pathways to genome duplication. Nature Publishing Group 2007-05-07 2007-04-03 /pmc/articles/PMC2360172/ /pubmed/17406359 http://dx.doi.org/10.1038/sj.bjc.6603718 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Dudderidge, T J
McCracken, S R
Loddo, M
Fanshawe, T R
Kelly, J D
Neal, D E
Leung, H Y
Williams, G H
Stoeber, K
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title_full Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title_fullStr Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title_full_unstemmed Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title_short Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
title_sort mitogenic growth signalling, dna replication licensing, and survival are linked in prostate cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360172/
https://www.ncbi.nlm.nih.gov/pubmed/17406359
http://dx.doi.org/10.1038/sj.bjc.6603718
work_keys_str_mv AT dudderidgetj mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT mccrackensr mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT loddom mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT fanshawetr mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT kellyjd mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT nealde mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT leunghy mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT williamsgh mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer
AT stoeberk mitogenicgrowthsignallingdnareplicationlicensingandsurvivalarelinkedinprostatecancer